Lisocabtagene maraleucel (Terminated appraisal) | Search results

Showing 1 to 2 of 2 results for lisocabtagene maraleucel (terminated appraisal)

Sort by

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) (TA987)
NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in adults. This is because Celgene did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Result type
Technology appraisal guidance
Published
10 July 2024
Show all sections
Sections for TA987
- Advice
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal) (TA1083)
NICE is unable to make a recommendation on lisocabtagene maraleucel (Breyanzi) after 1 systemic treatment in adults when a stem cell transplant is unsuitable. This is because the company did not provide an evidence submission.
Result type
Technology appraisal guidance
Published
23 July 2025
Show all sections
Sections for TA1083
- Advice